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        Ig heavy (IgH) and light (IgL) chain variable 
region exons are assembled from component 
V, D, and J segments in developing B lympho-
cytes. V(D)J recombination is initiated by the 
RAG1/2 endonuclease, which introduces 
DNA double-strand breaks (DSBs) between 
V, D, and J segments and fl  anking recombina-
tion signal sequences (RSs) (  1  ). Subsequently, 
cleaved coding segments are joined to form 
V(D)J exons and RSs are joined to form RS 
joins (  2  ). Both coding and RS joining are per-
formed by classical nonhomologous end-join-
ing (C-NHEJ), which is a major general DSB 
repair pathway in mammalian cells (  3  ). Xrcc4 
and DNA Ligase IV (Lig4) form a complex that 
is required for V(D)J recombination (  4, 5  ). In 
their absence, coding or RS ends are joined at 
low frequency, usually with substantial se-
quence deletion from one or both partners 
(  6, 7  ). In mice,   Xrcc4   inactivation results in se-
vere combined immune defi  ciency owing to 
inability to complete V(D)J recombination (  6  ). 
  In progenitor B (pro  –  B) cells in the mouse 
BM, productive assembly of variable region ex-
ons within the IgH locus (  Igh  ) on chromosome 
12 leads to production of IgH      chains that 
signal diff  erentiation to the precursor B (pre  –  B) 
cell stage in which IgL variable region exons 
are assembled (  8  ). Mice, like humans, have two 
IgL families, termed Ig     and Ig    , which are 
encoded by   Ig       and   Ig       loci that, respectively, 
lie on chromosomes 6 and 16. Ig     and Ig     ex-
pression is   “  isotype  ”   excluded, such that a 
given B cell usually expresses either Ig     or Ig    , 
but not both (  9  ). In mice,     95% of mature 
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  Nonhomologous end-joining (NHEJ) repairs DNA double-strand breaks (DSBs) during V(D)J 
recombination in developing lymphocytes and during immunoglobulin (Ig) heavy chain (IgH) 
class switch recombination (CSR) in peripheral B lymphocytes. We now show that CD21-
cre  –  mediated deletion of the   Xrcc4   NHEJ gene in p53-defi  cient peripheral B cells leads to 
recurrent surface Ig-negative B lymphomas (  “  CXP lymphomas  ”  ). Remarkably, CXP lympho-
mas arise from peripheral B cells that had attempted both receptor editing (secondary 
V[D]J recombination of Ig     and Ig     light chain genes) and   IgH   CSR subsequent to   Xrcc4   
deletion. Correspondingly, CXP tumors frequently harbored a CSR-based reciprocal chromo-
somal translocation that fused   IgH   to   c-myc  , as well as large chromosomal deletions or 
translocations involving   Ig       or   Ig      , with the latter fusing   Ig       to oncogenes or to   IgH  . Our 
fi  ndings reveal peripheral B cells that have undergone both editing and CSR and show them 
to be common progenitors of CXP tumors. Our studies also reveal developmental stage-
specifi  c mechanisms of   c-myc   activation via   IgH   locus translocations. Thus, Xrcc4/p53-
defi  cient pro  –  B lymphomas routinely activate   c-myc   by gene amplifi  cation, whereas 
Xrcc4/p53-defi  cient peripheral B cell lymphomas routinely ectopically activate a single 
  c-myc   copy. 
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ciency also results in extensive apoptosis of newly generated 
neurons and late embryonic death (  6  ), both of which can be 
rescued by defi  ciency for the p53 tumor suppressor (  31  ). 
In this context, p53 monitors the G1 cell cycle checkpoint, 
signaling apoptosis of certain cell types, such as neurons and 
progenitor lymphocytes, which harbor persistent DSBs (  32  ). 
However, as p53 defi  ciency does not rescue defective NHEJ 
associated with Xrcc4 defi  ciency, Xrcc4/p53  –  double-defi  cient 
mice are still immunodefi  cient and inevitably succumb to 
pro  –  B cell lymphomas that harbor RAG-dependent complex 
translocations (  33  ). These translocations usually join   IgH   on 
chromosome 12 to a region downstream of   c-myc   on chro-
mosome 15, resulting in dicentric 12;15 translocations and 
  c-myc   amplifi  cation via breakage  –  fusion  –  bridge cycles (  34  ). 
Such complex translocations are rare in human peripheral 
B cell lymphomas, which more frequently harbor reciprocal 
translocations that fuse   IgH  , or less frequently   IgL   loci, just 
upstream of   c-myc  , leading to ectopic   c-myc   activation (  35  ). 
  In the current study, we have asked whether inactivation 
of C-NHEJ in WT or p53-defi  cient peripheral B cells leads 
to peripheral B cell lymphoma with CSR or V(D)J recombi-
nation-associated   IgH   or   IgL   locus translocations. 
    RESULTS   
  Inactivation of   Xrcc4   in p53-defi  cient peripheral B cells 
leads to novel B cell lymphomas 
  We previously inactivated   Xrcc4   specifi   cally in transitional 
stage peripheral B cells by generating mice that harbored one 
copy of a loxP-fl  anked (fl  oxed)   Xrcc4   allele (  X  c    ) and one copy 
of an   Xrcc4  -null allele (  X         ) plus a transgene that drives Cre 
recombinase expression via a   CD21   promoter (termed   CX  c/  –      
mice) (  30  ). CD21 proteins are expressed during B cell develop-
ment at the time when immature transitional B cells diff  erentiate 
into mature long-lived peripheral B cells, including marginal 
zone B cells, follicular B cells, B1a (CD5  +  ), and B1b cells 
(  36  ). CD21cre mediates effi   cient Cre recombination in ma-
ture, but not immature, transitional B cells (  37  ). Thus,   CX  c/  –      
mice have normal IgM  +   splenic B cell numbers as   Xrcc4   is not 
deleted during early B cell developmental stages where V(D)J 
recombination occurs (  30  ).   Remarkably,   CX  c/  –      mice have a 
normal life span and are not cancer-prone (  Fig. 1 A  ), despite 
high levels of general and   IgH  -specifi  c genomic instability in 
ex vivo     CD40/IL-4  –  stimulated peripheral   CX  c/  –      B cells 
(  30  ). Analogous to what we previously found for B lymphoid 
and neuronal progenitors (  31  ), lack of   CX  c/  –      B cell transfor-
mation may refl  ect p53-dependent elimination of cells har-
boring DSBs and other types of genomic instability. To 
investigate this possibility, we bred   CX  c/  –      mice into a p53-
defi  cient background to generate   CX  c/     P      /        mice. 
  The majority of   CX  c/     P      /        mice become moribund by 
3.5  –  4.5 mo of age, with   >  50% succumbing to Xrcc4/p53-
defi  cient B lineage lymphomas that present predominantly in 
the mesenteric lymph nodes and that had deleted   Xrcc4   
(  Fig. 1, A and B ). The remaining  CX  c/     P      /        mice succumbed 
to thymic lymphomas and sarcomas characteristic of p53 de-
fi  ciency alone and which had not deleted   Xrcc4   (  Fig. 1 B  ). 
B lymphocytes are Ig      +  , with the remainder being Ig      +  . In that 
context,   Ig       assembly usually precedes that of   Ig       (  9  ). Thus, 
most Ig      +   B cells contain   Ig       in germline confi  guration, with 
  Ig       rearrangements occurring in cells in which both   Ig       al-
leles are rearranged out-of-frame or that harbor deletions of 
the J     segments,      enhancer, and/or C     exons (  9  ). Such de-
letions usually occur via rearrangement of V    s or an RS hep-
tamer in the J    -C     intron (IRS) to a bona fi  de RS 25 kb 
downstream of C     (3    RS) (  10  ). Recent analyses suggest that 
  Ig       deletions via 3    RS rearrangements may play a role in pro-
gression to   Ig       rearrangement (  11  ). 
  Expression of complete Ig (IgH/IgL) leads to IgM  +   
B lymphocytes, which ultimately down-regulate RAG ex-
pression to enforce allelic exclusion (  1  ). However, newly 
generated BM IgM  +   B lymphocytes that express autoreactive 
B cell receptors can maintain RAG expression and continue 
to rearrange   IgL   loci to generate new IgL chains in a tolerance 
process termed   “  receptor editing  ”   (  12  –  14  ). Receptor editing 
can replace rearranged   Ig       loci with secondary productive   Ig       
rearrangements, as well as with nonfunctional   Ig       rearrange-
ments or   Ig       deletions that may lead to   Ig       rearrangement 
(  12  –  14  ). Thus, Ig      +   B cells can be generated developmen-
tally from pre  –  B cells with two nonproductive   Ig       rearrange-
ments or via receptor editing from immature Ig      +   B cells. 
Receptor editing is initiated in immature BM B cells (  15, 16  ). 
Yet, several studies suggested   IgL   gene rearrangement, some-
times called   “  revision,  ”   in mouse and human peripheral 
B cells, including germinal center B cells (  17  –  21  ). However, 
many peripheral mouse RAG  +   B lineage cells are pro  –   or 
pre  –  B cells that migrate to the periphery after immunization 
(  22, 23  ), and knock-in reporter studies suggested that al-
though RAG genes are expressed in B cells that have just 
migrated from the BM (  24, 25  ), they are not reinduced in 
peripheral B cells once expression is terminated (  25, 26  ). 
  After antigen stimulation, mature IgM  +   peripheral B cells 
can undergo IgH class switch recombination (CSR), a recom-
bination/deletion process in which the IgH      constant region 
exons (C    ) are deleted and replaced by one of several sets of 
downstream C  H   exons (e.g., C    , C  	  , and C    ; referred to as C  H   
genes) (  27  ), leading to switching from IgM to another Ig class 
(e.g., IgG, IgE, or IgA). The activation-induced cytidine de-
aminase (AID) initiates CSR (  28  ) by deaminating cytidines in 
switch (S) regions (  29  ), which are 1  –  10-kb repetitive sequences 
located 5     of each C  H   gene. AID-generated lesions within the 
donor S     and a downstream acceptor S region are processed 
into DSBs, which are end-joined to complete CSR (  27  ). In con-
trast to V(D)J recombination, substantial CSR occurs in the 
absence of Xrcc4 or Lig4 (C-NHEJ) via an alternative end-
joining (A-EJ) pathway strongly biased to use microhomology 
(  30  ). However, CSR is signifi  cantly impaired in Xrcc4-defi  cient 
B cells owing to failure to join broken S regions because up to 
20% of Xrcc4-defi  cient B cells activated for CSR in vitro have 
  IgH   chromosomal breaks, with a substantial portion participat-
ing in chromosomal translocations (  30  ). 
  Inactivation of   Xrcc4   in mice results in impaired cellular 
proliferation and ionizing radiation sensitivity. Xrcc4 defi  -JEM VOL. 205, December 22, 2008 
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(Fig. S2 and Table S2). Likewise, eight additional CX  c/             P      /      
B lymphomas that were also heterozygous for a mutation in 
the 3     IgH regulatory region (CXPR lymphomas) had a sim-
ilar phenotype, including lack of surface Ig expression (un-
published data). As expected, we found little or no evidence 
of   Xrcc4   deletion in sorted BM B220  +  IgM        cells or in sorted 
HSA  high  CD21  low   peripheral immature B cells, but essentially 
complete   Xrcc4   deletion in purifi  ed HSA  low  CD21  high   mature 
splenic B cells (Fig. S3). By PCR, we occasionally observed 
very low levels of a product corresponding to   Xrcc4   deletion 
in BM and immature B cell samples, which theoretically may 
refl  ect very low-level deletion in earlier B cell stages, but 
which also may simply refl  ect recirculating peripheral B cells 
in the BM and/or low-level contamination of the sorted 
populations (unpublished data). Along with the appearance of 
these B lineage tumors being dependent on   Xrcc4   deletion via 
  CD21cre   expression at transitional B cell stage (  Fig. 1 B   and 
Fig. S3) (  30  ), these phenotypic characterizations indicate that 
CXP lymphomas, despite lack of surface Ig expression, de-
rive from peripheral B cells. 
    IgH  ,   Ig      , and   Ig       rearrangements in CXP tumors 
  Recurrent sIg        peripheral lymphomas have not been observed 
previously. To elucidate the basis for this striking phenotype, 
we fi  rst assayed for expression of IgH chains via Western 
blotting of tumor extracts. Most analyzed CXP B lymphomas 
lacked readily detectable IgH chain expression, although 
CXP62 expressed cytoplasmic      chains (  Fig. 2, B and C  ).   
Both normal and C-NHEJ  –  defi  cient pro  –  B lines display re-
arrangements of both J  H   alleles (  31  ). Assays of CXP tumor 
DNA for J  H   rearrangements via Southern blotting revealed 
that all primary CXP tumors showed J  H   rearrangements, along 
with varying degrees of a germline J  H   band (  Fig. 2 A  ). How-
ever, the germline band usually occurred in low levels and 
was often further reduced in passaged tumors (unpublished 
data), indicating derivation from non  –  B lineage cells within 
the tumor. Despite lack of detectable IgH expression, molec-
ular cloning demonstrated that CXP tumors contained struc-
turally normal in-frame or out-of-frame V(D)J rearrangements, 
indicating that they occurred before   Xrcc4   inactivation (see 
the following section). Finally, most CXP tumors had rear-
rangements in or around   IgH   S regions. At least fi  ve out of 
eight CXP tumors had clonal S    /C     rearrangements; three 
had one or more clonal S     rearrangements of which one was 
molecularly cloned (from CXP68) and found to be an S    2a 
to S     rearrangement; one CXP tumor had an S    2b rear-
rangement; and another had a clonal S    3 rearrangement in 
addition to the S    2a to S     rearrangement (Table S1 and 
Fig. S4, A and B, available at http://www.jem.org/cgi/content/
full/jem.20082271/DC1). Thus, most CXP tumors derived 
from peripheral B cells that had attempted   IgH   CSR. 
  No analyzed CXP tumor expressed readily detectable Ig     
and Ig     chains (  Fig. 2 B   and not depicted). Approximately 
60% of normal B cells have one productively rearranged   Ig       
allele and one germline allele, and     40% have one productive 
and one nonproductively rearranged or deleted J     allele (  38  ). 
In contrast, none of the   CP      /       ,   CX  c/  –     , or   CX  c/     P  +/        litter-
mates developed B lymphomas (  Fig. 1, A and B  ). Of eight 
  CX  c/     P      /        B lineage lymphomas (termed CXP lymphomas) 
characterized in detail, all were surface Ig negative (sIg       ) and 
all were B220  +  , CD43  low  , CD138/Syndecan-1  +  , and CD19  +   
(Fig. S1 A, available at http://www.jem.org/cgi/content/
full/jem.20082271/DC1). In addition, all had clonal   IgH   and 
  Ig       rearrangements and many had clonal   Ig       rearrangements, 
even though they usually lacked expression of IgH and IgL 
proteins (Table S1; see below). RNA expression analyses in-
dicated that   CXP   lymphomas lacked expression of     5 and 
Vpre  –  B, two diagnostic early B cell markers, but did show 
very low-level RAG expression (Fig. S1, B and C, and not 
depicted). We also analyzed six additional Xrcc4/p53-defi  -
cient B lymphomas derived from   CX  c/        mice in which the 
p53 gene was also fl  oxed (  CX  c/     P  c/c  )   and found that the ma-
jority had a phenotype similar to   CX  c/     P      /        lymphomas 
    Figure 1.         Establishment of the CXP B cell lymphoma model via 
conditional inactivation of   Xrcc4   in CD21Cre-expressing, p53-
defi  cient mice.   (A) Kaplan-Meier survival curve: percent survival of CX  c/    P    /    
(  n   = 24); CX  c/    P +/      ( n   = 25); CP     /     ( n   = 15); and CX  c/      ( n   = 25) mice ver-
sus age in days is shown. (B) Tumor types that developed in the indicated 
cohorts of CX  c/    P    /     and  CP    /     mice. The number of mice that developed 
a given type of tumor is indicated at the left. Deletion of the fl  oxed   Xrcc4  
allele in given tumors is indicated at the right. nd, not determined; N/A, 
not applicable. The asterisk indicates CX  c/    P    /     mice that developed os-
teosarcoma or thymic lymphomas, in addition to B cell lymphomas.     3082 LYMPHOMAS FROM EDITING AND SWITCHING B CELLS   | Wang et al. 
rearrangement in CXP tumors via Southern blotting and 
found rearrangement and/or deletion of the 3    RS sequences 
in all analyzed tumors (  Fig. 3 A   and Fig. S5 A). As normal 
3    RS rearrangements do not result in deletions larger than 
a few nucleotides (  39  ), we tested the hypothesis that 3    RS 
rearrangements in CXP lymphomas had occurred after   Xrcc4   
inactivation by cloning and sequencing rearrangements. Of 
three RS rearrangements isolated, two had apparent V     and 
3    RS region junctions accompanied by large deletions (30  –  80 
bp into V     and 26  –  43 bp beyond 3    RS sequence), whereas 
the other had a normal V     to 3    RS join (Fig. S5 B). In addi-
tion, Southern blotting with a 3    RS probe showed CXP163 
had an aberrant RS rearrangement with a large deletion 
(  >  4 kb) downstream of the 3    RS sequence (Fig. S5 C). 
Southern blotting also showed that a signifi  cant proportion of 
CX  c/             P  c/c   B lymphomas (four out of six; Fig. S2) and CXPR 
B lymphomas (fi  ve out of eight; not depicted) had deleted 
one or both   Ig       alleles. We conclude that deletional   Ig       3    RS 
rearrangements in CXP tumors are reminiscent of those associ-
ated with attempted V(D)J joining in the absence of C-NHEJ, 
suggesting they occurred in progenitors of CXP tumors sub-
sequent to   Xrcc4   inactivation via   CD21cre   expression. 
  Complete   Ig       deletion is generally observed in a subset of 
mouse peripheral Ig      +   B cells (  39  ). Therefore, we assayed CXP 
lymphoma DNA by Southern blotting with probes to detect 
V    J     rearrangements within both Ig     clusters (Fig. S5 D). 
These analyses demonstrated that at least six out of nine as-
sayed CXP or CX  c/             P  c/c   B cell lymphomas had clear-cut   Ig       
rearrangements, with CXP62, 162, and 163 showing rear-
rangements of both alleles (Fig. S5, A and D). Southern blot-
ting analyses also showed that several analyzed CXPR B 
lymphomas had   Ig       rearrangements (unpublished data). To 
elucidate the nature of the   Ig       rearrangements in CXP tu-
mors, we performed PCR using V    1/V    2- and J    1/J    2-spe-
cifi  c primers to isolate six diff  erent rearrangements involving 
one or the other J     cluster (  Fig. 3 B   and Fig. S5 E). Nearly 
all isolated   Ig       rearrangements involved joining of sequences 
in or upstream of a V     to sequences in or downstream of a J    , 
with the majority of breakpoints leading to deletions larger 
than the few basepair deletions observed from one or both 
segments in normal V    J     joins (  Fig. 3 B   and Fig. S5 E) (  40  ). 
As PCR only allows isolation of junctions within the primer 
boundaries, we cloned several   Ig       rearrangements from ge-
nomic phage libraries generated from CXP163 and CXP162 
DNA and identifi  ed a deletional rearrangement that went 
    2.8-kb and     800-bp, respectively, beyond the V    1 and 
J    1 segments, as well as aberrantly deleted RS rearrangements 
(  Fig. 3 B   and Fig. S5 E). Overall, the observed pattern of   Ig       
rearrangements in CXP lymphomas, namely large deletions 
from the participating segments on one or both sides of the 
join, is fully consistent with the types of junctions previously 
characterized for attempted V(D)J recombination of endoge-
nous loci in C-NHEJ  –  defi  cient progenitor B or T lympho-
cytes (  3, 41  ). Therefore, CXP tumors appear to arise from 
B cells that attempted   Ig       rearrangement subsequent to   Xrcc4   
deletion via   CD21cre   expression. 
We assayed for J     rearrangements by Southern blotting and 
found that all eight analyzed CXP tumors lacked both copies 
of the J     locus (  Fig. 3 A   and Fig. S5 A, available at http://www
.jem.org/cgi/content/full/jem.20082271/DC1).   Although 
there was a variable level of a germline-sized J     band, the level 
was far below that expected for a single germline allele and 
roughly correlated with that of contaminating nonlymphoid 
DNA as judged by the J  H   Southern blot (  Fig. 2 A  ). Southern 
blotting revealed that CXP tumors also lacked both copies 
of the C     exons (  Fig. 3 A  ). We tested for downstream RS 
    Figure 2.         CXP lymphomas harbor clonal J  H   rearrangements, but do 
not express IgM or IgL chains.   (A) Southern blot analyses of CXP lym-
phoma genomic DNA samples for rearrangement or deletion of J  H   loci (rep-
resentative of at least two separate analyses for each sample). (B) Western 
blot analyses of CXP lymphoma cellular extracts for expression of      heavy 
chain and      or      light chains using HRP-conjugated anti-IgM (     heavy 
chain specifi  c), anti-    , or anti-     antibodies, respectively. (C) Western blot 
analyses of CXP lymphoma cellular extracts for expression of      heavy 
chains using HRP-conjugated anti  –  mouse IgG antibody. An    -tubulin  anti-
body was used to generate a loading control in both panels. PP indicates 
extracts from Peyer  ’  s patches. Data presented in this fi  gure shows results 
representative of two or three independent sets of analyses.    JEM VOL. 205, December 22, 2008 
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probe) was fused proximal to the centromeric portion of 
Chr15 in or just upstream of   c-myc   to yield the reciprocal 
t(15;12) translocation (  Fig. 4 A   and Fig. S6 A). CXP221 har-
bored a clonal t(12;15) translocation involving   IgH   and   c-myc   
loc, but lacked the reciprocal t(15;12) translocation, and 
instead contained a clonal t(15;7) translocation (Fig. S6 A). 
Based on FISH, neither   c-myc   nor   IgH   appeared amplifi  ed in 
CXP tumors. Similar to CXP tumors, three out of four ana-
lyzed CX  c/     P  c/c   B lymphomas and six out of six CXPR tu-
mors analyzed had translocations involving chromosomes 12 
and 15 that involved the   IgH   and   c-myc   loci (Fig. S6 A, Table 
S4, and not depicted). 
  To further analyze CXP B lymphoma t(12;15) and 
t(15;12) translocation junctions, we performed Southern 
blotting with probes within or just upstream of   c-myc   (Fig. S6 B). 
These analyses demonstrated that the six CXP lymphomas 
with t(12;15) translocations had clonal rearrangements in or 
  C-NHEJ suppresses oncogenic CSR-related translocations 
between   IgH   and   c-myc   
  Spectral karyotyping (SKY) revealed that six out of eight 
characterized CXP tumors (CXP68, 153, 162, 163, 221, and 
2152) harbored clonal translocations between chromosomes 
12 and 15, possibly involving   IgH   (Chr12) and   c-myc   (Chr15) 
loci (  Fig. 4 A  , Table S3, and Fig. S6 A, available at http://
www.jem.org/cgi/content/full/jem.20082271/DC1).   To 
test this possibility, we performed fl  uorescence in situ hybrid-
ization (FISH) with 5     and 3       IgH   BAC probes plus a BAC 
probe containing   c-myc   (  Fig. 4 A  ). These analyses demon-
strated that 5 out of 6 tumors (CXP68, 153, 162, 163, and 
2152) harbored reciprocal t(12;15) and t(15;12) translocations 
in which the centromeric portion (C  H  ) of   IgH   (3     IgH probe) 
was fused proximal to the telomeric portion of Chr15 in or 
around   c-myc   (c-myc BAC probe) to yield the t(12;15) trans-
location, and the telomeric (V  H  ) portion of   IgH   (5     IgH 
    Figure 3.         Aberrant IgL rearrangements in CXP lymphomas.   (A, right) Southern blot analyses for J     rearrangements in CXP lymphoma genomic DNA 
using BamHI digestion and the 3     J    and  C    probes indicated in schematic at top of panel. (left) Southern blot analysis for RS rearrangements in CXP 
lymphoma DNA using BglII digestion and the indicated RS0.8 probe. Germline (GL) bands and their known sizes are indicated (arrows). Blots were per-
formed at least two times. (B) Assays for rearrangements occurring in or near V     and  J    segments in DNA samples from CXP lymphomas. Rearrange-
ments were isolated either by PCR or by cloning from     -phage genomic DNA libraries generated from individual tumor DNA samples. Black arrows denote 
the position of the PCR primers used for the studies, and primer sequences are indicated in the Materials and methods section. The two breakpoints for a 
given rearrangement in the vicinity of V     and  J    in a particular tumor are indicated by the same number with the breakpoint in the J     region  indicated 
by a (  ‘  ) symbol. PCR analyses were performed at least three times from one or multiple independent DNA samples from a given tumor. PCR fragments 
were subcloned into the pGEM vector, and 10  –  20 subclones were sequenced. Identical rearrangements that were isolated from   >  80% of the subclones 
were scored as clonal rearrangements. At least two independent phage clones were isolated from each genomic library and the junctions found in phage 
clones were independently confi  rmed as clonal junctions in a given tumor by PCR analyses of tumor cell DNA. Sequences of cloned V     and  J    rearrange-
ment junctions are shown in Fig. S5E.     3084 LYMPHOMAS FROM EDITING AND SWITCHING B CELLS   | Wang et al. 
p53-defi  cient pro  –  B cell tumors (  42  ). Thus, all CXP tumors 
overexpressed a   myc   family gene. 
  To further elucidate   IgH  /  c-myc   translocations in CXP 
tumors, we isolated translocation junctions by screening 
genomic DNA libraries from individual tumors. Nucleotide 
sequence analyses showed that all fi  ve characterized junctions 
corresponded to translocations between   IgH   and   c-myc   (  Fig. 4 
B   and Fig. S6 D). All junctions on Chr12 (  Fig. 4 B  , red), in-
cluding those associated with both t(12;15) and t(15;12) oc-
curred within   IgH  , most in the C  H   region within or around 
S regions consistent with derivation via aberrant CSR. The 
CXP153 t(12;15) junction linked S    1 to sequences just 5     of 
  c-myc   (junction 1, CXP153), whereas the t(15;12) linked S  μ   
to sequences in the fi  rst intron of   c-myc   (  Fig. 4 B   and Fig. S6 D). 
The CXP163 t(12;15) junction linked I     to a sequence 
around   c-myc   (Fig. S6 B and not depicted), with one additional 
tumor that lacks a t(12;15) translocation (CXP62; detailed in 
the following section), also showing a clonal   c-myc   rearrange-
ment (Fig. S6 B). Southern blotting confi  rmed that none of the 
CXP tumors had amplifi  ed   c-myc   (Fig. S6 B). Northern blotting 
with a   c-myc   probe further demonstrated that all CXP tumors 
with t(12;15) translocations had greatly increased   c-myc   expres-
sion, indicating ectopic overexpression from a single copy of the 
translocated   c-myc   gene (Fig. S6 C). Of note, only two CXP tu-
mors lacked t(12;15) translocations; however, one (CXP62) ac-
tivated   c-myc   via an   Ig      /  c-myc   translocation (see below) and the 
other (CXP35) had a complex Chr12 translocation that resulted 
in   N-myc   amplifi  cation and overexpression (Fig. S6 C and 
Fig. S7 A, available at http://www.jem.org/cgi/content/full/
jem.20082271/DC1) reminiscent of that observed in Artemis/
    Figure 4.         Reciprocal   IgH/c-myc   translocations in CXP lymphoma.   (A) SKY, FISH, and chromosome paint analyses (Chr12 pink, Chr15 green) for   IgH/
c-myc   translocations in CXP163 and CXP153. A   3   IgH   BAC (light green) and a   c-myc   BAC (light green) were used in combination with chromosome 
paints to detect t(12;15) translocations. The t(15;12) translocation, not detectable by SKY, was visualized using the 5      IgH   BAC (pink) and a Chr15 paint 
(green). At least 15 metaphase spreads were analyzed for SKY, FISH, and chromosomal paints, respectively, for each CXP tumor. Translocations shown 
were observed in the majority of metaphases, and were scored as clonal if observed in   >  80% of metaphases. (B) Schematic of   IgH/c-myc   translocation 
breakpoint junctions cloned and sequenced from     -phage tumor genomic DNA libraries. At least two independent phage clones were isolated from each 
genomic DNA library, and breakpoint junctions identifi  ed within them were further independently confi  rmed by PCR and sequencing from the appropriate 
tumor DNA samples. The numbers on the top indicate t(12;15) translocation breakpoints and the same numbers containing a (  ’  ) on the bottom indicate 
the   “  reciprocal  ”   t(15;12) translocation breakpoints in the corresponding tumor: CXP153 (junction 1 and 1  ’  ), 163 (junction 2 and 2  ’  ), and 68 (junction 3   ).   JEM VOL. 205, December 22, 2008 
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translocations of Chr6 (which contains   Ig      ) in one of eight 
CXP tumors and in two of four characterized CX  c/     P  c/c   B 
lymphomas (Tables S3 and S4). Notably two tumors (CXP162 
and CX  c/     P  c/c   1893) harbored clonal t(6;16) translocations 
that fused   Ig       to Chr6. However, cytogenetic analyses indi-
cated that these t(6;16) translocations did not harbor   Ig       (Fig. 
S7 A), although   Ig       may still have been involved and deleted 
during joining (see the following section). 
  Characterization of several   Ig       breakpoints by FISH and/
or molecular cloning revealed partner loci and showed that 
sequences around translocation junctions lacked somatic hy-
permutation (SHM; Fig. S7 B and not depicted). By SKY, 
the CXP62 tumor, which was the only one that did not acti-
vate a   myc-  family gene by an   IgH   translocation, contained 
reciprocal t(16;15) and t(15;16) translocations, which juxtaposed 
the   Ig       P12 BAC probe to the telomeric portion of Chr15 in 
288 bp upstream of   c-myc   exon 1, and the t(15;12) linked se-
quences between J  H3   and J  H4   to sequences 289 bp upstream of 
  c-myc   exon 1 (  Fig. 4 B   and Fig. S6 D); notably, the CXP163 
t(15;12) junction occurred downstream of a nonproductive 
V  H  (D)J  H   rearrangement (  Fig. 5 B  ), indicating that it did not 
happen during V(D)J recombination and, rather, may have 
resulted in association with a large deletion from a breakpoint 
downstream in I    -S     region. Finally, the t(15;12) CXP68 
junction linked sequences near I    3 to sequences 1.4-kb up-
stream of   c-myc   exon 1 (  Fig. 4 B  ), again, likely resulting from 
attempted CSR to S    3. Four of these fi  ve cloned junctions 
contained junctional microhomology suggestive of A-EJ 
(Fig. S6 D). Overall, CXP   IgH  /  c-myc   translocations are re-
markably similar to those of human sporadic Burkitt  ’  s lym-
phoma that fuse   IgH   S regions upstream of   c-myc  . 
  Because of the location of the characterized translocation 
junctions downstream of the   IgH   J  H   region, we considered 
the possibility that many CXP tumors were sIg        because they 
separated a productive V  H  (D)J  H   exon from the C  H   region. In 
this context, two out of three analyzed CXP tumors with 
  IgH/c-myc   translocations (CXP68 and CXP153) contained an 
in-frame (productive) V  H  (D)J  H   rearrangement fused to the 
  c-myc   locus on Chr15; whereas the other (CXP163) involved 
a translocated nonproductive V  H  (D)J  H   rearrangement (  Fig. 5, 
A  –  C  ).   In CXP163, which has the nonproductive V  H  (D)J  H   
translocated to   c-myc  , the other Chr12 was involved in a 
t(12;16) translocation that may have resulted in loss of the 
presumably productive V  H  (D)J  H   exon, as the breakpoint is 
centromeric to   IgH   (Fig. 7 A and Fig. S7 A). Of the four 
V  H  (D)J  H   junctions and downstream fl  anks sequenced (3,884 
bp), one carried two somatic point mutations and the other 
three lacked mutations (unpublished data). Finally, cloned 
V  H  (D)J  H   rearrangements appeared normal in respect to junc-
tional deletions (  Fig. 5, A  –  D  ), indicating they occurred in 
C-NHEJ  –  profi  cient cells. Therefore, primary V(D)J recom-
bination at the   IgH   locus was normal in B lineage cells that 
gave rise to CXP lymphomas. 
  CXP lymphomas frequently harbor   Ig       translocations 
  SKY analyses demonstrated that fi  ve out of eight character-
ized CXP B lymphomas (CXP35, 62, 68, 162, and 163), 
many of the same ones that harbored translocations between 
chromosomes 12 and 15, harbored Chr16 translocations to 
various other chromosomes with two others (CXP153 and 
2152) harboring nonclonal Chr16 translocations (  Fig. 6 A  , 
Table S3, and Fig. S7 A).   In contrast to the Chr12 transloca-
tions, all but one Chr16 translocation (i.e., CXP62) appeared 
nonreciprocal (  Fig. 6 A   and Fig. S7 A), similar to RAG-initiated 
oncogenic   IgH   translocations in Xrcc4/p53  –  defi  cient pro  –  B 
lymphomas (  34  ). As the   Ig       locus is on Chr16, we used FISH 
with three diff  erent BAC probes covering the   Ig       locus to 
determine whether the Chr16 breakpoints involved   Ig       
(  Fig. 6 A  ; P12 is centromeric to   Ig      , E14 spans both   Ig       clus-
ters, P9 is telomeric to   Ig      ). These analyses revealed that all 
fi  ve Chr16 breakpoints occurred directly within various re-
gions of   Ig       (  Fig. 6 A   and Fig. S7 A). We also observed clonal 
    Figure 5.         CXP lymphomas harbor normal V(D)J rearrangements in 
IgH locus.   Nucleotide sequence analysis of primary V  H (D)J H   rearrange-
ments cloned from the following: CXP153 by both     -phage library and 
PCR (A); CXP163 by     -phage library (B); CXP68 by PCR (C); and CXP2152 
by PCR (D). Additional sequence analyses revealed that CXP153 had a 
productive V7183-D-JH2 rearrangement juxtaposed into to the fi  rst in-
tron of   c-myc   and CXP163 has a nonproductive VH12-D-JH2 rearrange-
ment juxtaposed to the sequence upstream of   c-myc   exon1. V regions are 
shown in blue and J regions in red. The open reading frame is indicated 
under the DNA sequence. PCR analyses were performed at least three 
times from one or multiple independent tumor DNA samples. PCR frag-
ments were subcloned into pGEM vector, 10  –  20 subclones were se-
quenced, and identical rearrangements observed in   >  80% clones were 
scored as clonal rearrangements.     3086 LYMPHOMAS FROM EDITING AND SWITCHING B CELLS   | Wang et al. 
  Comparative genomic hybridization analyses of CXP tumors 
  We used comparative genomic hybridization (CGH) to assay 
for sequence copy number diff  erences among tumor and con-
trol tissues samples. Among the four samples derived from the 
CXP or CX  c/     P  c/c   cohort, three had clearly lost one copy 
of either the entire Chr6 or a large region of Chr6, with 
the boundary of the loss occurring near or spanning   Ig       
(Fig. S8, available at http://www.jem.org/cgi/content/
full/jem.20082271/DC1, and not depicted). Out of nine 
CXPR B lymphoma DNAs analyzed, seven again had a clear 
loss of one copy of the entire Chr6 or a large region that in 
two extended directly from   Ig       (Fig. S8 and not depicted). 
CGH also showed focal deletion of   Ig       in most analyzed 
CXP, CX  c/     P  c/c  , or CXPR tumors (Fig. S8 and not de-
picted), which is consistent with results of Southern blotting 
the t(16;15) translocation, and the   Ig       P9 and E14 BAC 
probes to the centromeric portion of Chr15 in the t(15;16) 
translocation (  Fig. 6 A  ). Based on analyses of cloned junc-
tions, the t(16;15) translocation fused sequences upstream of 
J    1 to sequences 5     of   c-myc   exon 1 (  Fig. 6 B   and Fig. S7 B), 
which led to high level expression of   c-myc   transcripts (Fig. S6 C), 
whereas the t(15;16) translocation contained the reciprocal 
product (Fig. S7 B). FISH analyses of the complex t(12;12;16) 
translocation that led to   N-myc   amplifi  cation in CXP35 
revealed that it involved both   Ig       and   IgH   loci (Fig. S7 A). 
Likewise, FISH analyses of the nonreciprocal t(12;16) CXP68 
translocation revealed colocalization of 3       IgH   and   Ig       P9 
BAC probes at the junction (  Fig. 6 A  ). By phage cloning, we 
mapped the CXP68 breakpoint to C  
   in   IgH   and just 3     of 
J    2 in   Ig       (  Fig. 6 B   and Fig. S7 B). 
    Figure 6.         Recurrent chromosome 16 translocations.   (A) SKY/FISH analyses of   Ig     translocations in CXP lymphomas. (A, top) schematic map of   Ig    
locus in germline confi  guration and the location of the three BACs used for FISH (P9, E14, and P12).(bottom) SKY revealed a t(12;16) translocation in 
CXP68, and a reciprocal t(16;15) and t(15;16) translocation in CXP62. FISH and chromosome paints (Chr12 pink, Chr16 light blue or white, Chr15 green) 
showed the breakpoints of Chr16 translocations occurred in different regions of the   Ig     locus, indicated by yellow lightning symbols over metaphases 
hybridized with different   Ig     BACs.   3   IgH   (pink) and   P9   (light blue) BACs were colocalized at the junction of t(12;16) in CXP68. CXP62 has a reciprocal 
translocation with P12 BAC (white) on the der(16)t(16;15) and E14 and P9 (white) BACs on the der(15)t(15;16). At least 15 metaphase spreads were ana-
lyzed for each of the cytogenetic analyses, and representative clonal translocations observed in   >  80% of the metaphases are shown. (B, top) Cloning of 
t(12;16) breakpoints from a genomic library made from CXP68 DNA. Nucleotide sequence analyses of cloned junction (shown in Fig. S7 B) indicated 
breakpoints occurred between C  
   in IgH and J    2 in Ig     locus. (bottom) Cloning of t(16; 15) breakpoints from a genomic library made from CXP62 DNA. 
Nucleotide sequence analyses indicated breakpoints occurred between sequences upstream of   c-myc   exon 1 and J   1  with  3     Ig     enhancer in close proxim-
ity. At least two independent phage clones were isolated from each genomic library and the junctions found in phage clones were independently con-
fi  rmed as clonal junctions in a given tumor by PCR analyses of tumor DNA sample. Fig. S7 is available at http://www.jem.org/cgi/content/full/jem
.20082271/DC1.   JEM VOL. 205, December 22, 2008 
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might refl  ect RAG versus AID-dependent DSB initiation in 
  IgH   and/or   c-myc  , other diff  erential stage-specifi  c mechanisms 
that lead to DSBs in and around   c-myc  , stage-specifi  c diff  er-
ences in nuclear localization of   IgH   and   c-myc   loci, or mecha-
nisms that diff  erentially activate   c-myc   after translocation, 
including stage-specifi  c IgH enhancer activities. As both Xrcc4/
p53-defi  cient pro  –  B and CXP peripheral B cell lymphomas 
frequently have   IgH/c-myc   junctions that appear to be medi-
ated by A-EJ, repair pathway choice is not likely to be a major 
factor in generating a particular form of translocation. Given 
the uniform and recurrent   IgH/c-myc   translocations, the CXP 
B lymphoma system should allow putative roles of cis ele-
ments and other factors to be tested. 
  CXP lymphomas also frequently harbor chromosome 16 
translocations that involve aberrant V(D)J recombination of 
  Ig       after   Xrcc4   deletion. At least one CXP   Ig       translocation 
was oncogenic. CXP62 had reciprocal t(15;16) and t(16;15) 
translocations, the latter of which fused the downstream por-
tion of   Ig       to sequences just upstream of   c-myc  , resulting in 
ectopic   c-myc   activation, reminiscent of   Ig    /c-myc   transloca-
tions observed in certain human B lymphomas (  35  ). Charac-
terization of additional CXP   Ig       translocations may lead to 
identifi  cation of additional oncogenes. Notably, we also ob-
serve loss of all or part of one copy of chromosome 6 with 
some large deletions extending from the vicinity of   Ig      . The 
latter fi  ndings suggest that rearrangements of   Ig      , likely in as-
sociation with aberrant editing, may also lead to translocations 
or chromosome loss. In the latter context, unrepaired DSBs 
can lead to chromosome loss in yeast (  48  ). The frequent loss 
of all or a large portion of chromosome 6 in CXP tumors is 
striking and suggests a potential role in etiology of these tu-
mors, perhaps by deletion of a tumor suppressor sequence. 
  More than 95% of mouse peripheral B cells express Ig     
and, correspondingly, have V    J     joins on one or both   Ig       al-
leles and   Ig       in germline confi  guration (  9  ). A small percent-
age of mouse B cells express Ig    , and these have   Ig       alleles that 
are nonproductively rearranged or deleted by 3    RS or related 
rearrangements (  39, 49  ). Notably, Ig    -expressing mouse 
B cells frequently arise via receptor editing, often in the context 
of   Ig       deletion via 3    RS rearrangement (  39  ). Thus, it is strik-
ing that CXP lymphomas frequently had clonal   Ig       deletions 
via aberrant V     to 3    RS rearrangements and aberrant V     to 
J     rearrangements, with both types of rearrangements occur-
ring subsequent to   CD21cre   expression. Based on these fi  nd-
ings, we speculate that a common CXP tumor progenitor 
derives from an Ig    -expressing B cell that attempted receptor 
editing subsequent to   Xrcc4   deletion. Attempted editing in 
the absence of Xrcc4 would lead to aberrant rearrangement/
deletion of   Ig       and progression to   Ig       rearrangement, which 
also would be aberrant. Thus, editing Xrcc4-defi  cient B cells 
would lose IgL expression caused by inability to undergo 
productive IgL editing. 
  As a working model, we suggest that aberrant receptor 
editing in CXP tumor progenitors generates an initial trans-
forming event and/or activates aberrant CSR through loss of 
parts of chromosome 6 or translocations of   Ig      . Aberrant 
analyses. In contrast, three thymic lymphomas and two fore-
brain tumors, most likely of glial origin, analyzed did not 
show loss of Chr6 or a large region proximal to   Ig       (Fig. S8 
and not depicted). 
    DISCUSSION   
  Xrcc4 defi  ciency in peripheral B cells does not predispose to 
B cell lymphoma, despite dramatic   IgH   instability in Xrcc4-
defi  cient B cells activated for CSR by treatment with     CD40 
plus IL-4 (  30  ). In this context,     CD40 plus IL-4  –  activated 
splenic CXP B cells had at most a very modest increase in 
  IgH   breaks compared with activated Xrcc4-defi  cient periph-
eral B cells (28   ±   13% versus 17   ±   7% of metaphases containing 
  IgH   breaks). Yet,   CD21cre   deletion of   Xrcc4   in p53-defi  cient 
peripheral B cells, or deletion of both genes in peripheral 
B cells, recurrently led to sIg        B lymphomas that harbor acti-
vated   myc  , likely refl  ecting the critical role of p53 in eliminat-
ing B cells with activated   c-myc   expression and/or eliminating 
B cells with high genomic instability (  33, 43, 44  ). CXP 
B lymphomas are remarkable in several ways. First, most 
CXP lymphomas arise from B cells that have attempted   IgH   
CSR and a majority appear to arise from B cells that have 
undergone receptor editing, with both processes occurring 
after   Xrcc4   inactivation by CD21Cre. Second, many CXP 
tumors harbored two separate, clonal translocations that, re-
spectively, involved   IgH   and   IgL   loci. Occurrence of clonal 
  IgH   and   IgL   translocations in the same tumor may refl  ect dual 
CSR and editing activities of B cells from which they arose. 
In this context, some CXP lymphomas had clonal transloca-
tions that fused   IgH   and   Ig      , clearly indicating simultaneous 
presence of breaks in both loci in tumor progenitors. As out-
lined below, these unusual features of CXP tumors have novel 
implications for B cell developmental processes and for onco-
genic translocation mechanisms. 
  Germline Xrcc4 plus p53 defi  ciency in mice leads to pro  –
  B lymphomas with RAG-dependent translocations that fuse 
J  H   sequences to sequences far downstream of c-  myc,   resulting 
in dicentric chromosomes and   c  -  myc   activation via breakage-
fusion-bridge amplifi  cation (  34  ). Thus, it is remarkable that 
inactivation of same two genes in mature B cells recurrently 
leads to ectopic activation of a single copy   c-myc   gene by fu-
sion of   IgH   into its upstream region, analogous to similar 
  IgH  /  c-myc   translocations in human Burkitt  ’  s lymphoma and 
diff  use large B cell lymphomas (  35  ). In pristane- or IL-6  – 
induced mouse plasmacytomas, similar   IgH  /  c-myc   translocations 
occur and are initiated by AID (  45, 46  ). In this context, CXP 
lymphoma   IgH  /  c-myc   translocations occur in and around   IgH   
S regions and downstream of normal V  H  (D)J  H   exons, indicat-
ing their likely selection from the abundant pool of   IgH   transloca-
tions that result from aberrant CSR in activated Xrcc4-defi  cient 
peripheral B cells (  30  ). As the intronic IgH enhancer is gen-
erally absent from CXP   IgH/c-myc   translocations, long-range 
3     IgH regulatory region activity (  47  ), or that of unknown 
  IgH   regulatory elements, may ectopically activate   c-myc  . The 
recurrent diff  erences in   IgH/c-myc   translocations in Xrcc4/
p53-defi  cient pro  –  B versus CXP peripheral B cell tumors 3088 LYMPHOMAS FROM EDITING AND SWITCHING B CELLS   | Wang et al. 
locations indicates that inability to productively complete 
receptor editing confers a major predisposition to transforma-
tion of peripheral CXP B cells. Perhaps editing CXP B cells 
represent a larger fraction of the CD21-expressing B cell pool 
than anticipated or are enriched in certain locations. For ex-
ample, receptor editing might especially contribute to anti-
body diversifi  cation in B cells of the gut-associated lymphoid 
tissue (e.g., mesenteric lymph nodes), where the CXP tumors 
appear to arise most frequently and in which lymphocytes are 
chronically activated and driven into immune responses by 
products of the gut microfl  ora. 
    MATERIALS AND METHODS   
  Mice.       CD21cre  /  Xrcc4    c/      mice were generated as previously described (  30  ) 
and crossed into p53 germline-defi  cient mice (  56  ) or mice carrying condi-
tional p53 alleles (  57  ). Animal work was approved by the Institutional Ani-
mal Care and Use Committee of Children  ’  s Hospital Boston. 
  Southern, Northern, and Western blot.     Genomic DNA was isolated 
from tumor masses or normal tissues from control mice, and Southern 
blotting was performed as previously described (  58  ). 3    J     probe was a 1-
kb XbaI  –  HindIII fragment from plasmid pSPIg8 containing the J     and 
C     region (  59  ), or generated by PCR using the following primers: 3     J    5, 
5    -  CATCCAAGAGATTGGATCGGAGAATAAGCA-3      ; MA35, 5    -  AAC-
ACTGGATAAAGCAGTTTATGCCCTTTC-3      ; and plasmid pSPIg8 
as template. C     probe was a 1.7-kb HindIII  –  BglII fragment covering the 
C     region. RS probes were previously described (  60  ). RNA samples were 
extracted from tumor masses or normal tissues from control mice using 
TriPure Isolation Reagent (Roche). Northern blotting was performed fol-
lowing a standard protocol. Western blotting was performed using HRP-
conjugated antibodies at 1:1,000 dilution (HRP goat anti  –  mouse IgM 
[     chain  –  specifi   c antibody], HRP goat anti  –  mouse     , HRP goat anti  –
  mouse     , and HRP goat anti  –  mouse IgG [     chain  –  specifi  c  antibody]; 
SouthernBiotech). Additional primers used for generating probes are detailed 
in the Supplemental materials and methods (available at http://www.jem
.org/cgi/content/full/jem.20082271/DC1). 
  Phage and PCR cloning.     Tumor DNA samples were digested to com-
pletion with EcoRI, and fragments were cloned into either     ZAP II vector 
(Stratagene) or     DASH II vector (Stratagene) according to the size of the frag-
ments. Libraries were screened according to standard protocols (Stratagene) 
using C    1 or J    2 probe for      rearrangements or translocations;   c-myc   probe 
A or   c-myc   probe D for   c-myc   translocations; C    , C    1, and S    1 probes for S 
region rearrangement and translocations (see details for probes in the Supple-
mental materials and methods). Single plaques were purifi  ed, subcloned, and 
sequenced. In the case of     ZAPII clones, the inserts were excised according to 
the protocol provided (Stratagene). Positive clones were verifi  ed by restriction 
analysis and hybridization. Sequencing of subcloned inserts was performed us-
ing T7 or T3 primers (DF-HCC DNA Resource Core). To obtain junctional 
sequences, internal primers were required for some tumors. For PCR clon-
ing of Ig     rearrangements: Vlambda1int:5    -ttgtgactcaggaatctgca-3     and Lamin 
5    -ggagcagtctgaaatgagacaaagcat-3     were used. Additional primers used for 
PCR cloning of junctions are detailed in Online supplemental material. 
  SKY and FISH analyses.     Preparation of metaphase chromosomes, SKY 
analyses, FISH, and whole-chromosome painting using single-chromosome  –
  specifi  c paints were performed as previously described (  61  ). FISH probes 
were as follows: a BAC that covered the 3     region of the   IgH   locus encom-
passing   3     IgH   enhancer and 100 kb downstream (3     IgH BAC), a BAC just 
upstream of the   IgH   V  H   region (5     IgH BAC) as described previously (  62  ), 
and a BAC that contained the   c-myc   gene (RP23-307D14,   c-myc   BAC). 
BACs for Ig     regions are RP23-382P9, RP23-60E14, RP23-374P12, and 
BACs for Ig     regions are RP23-84F6 and RP23-64I9. All the BACs were 
obtained from BACPAC CHORI database, except for the IgH BACs. 
CSR in the absence of Xrcc4 would lead to a high level of 
  IgH   translocations (  30  ), including   IgH/c-myc   translocations 
that would complete the transformation process. In the case 
of the CXP tumor that harbors an   Ig    /c-myc   instead of an 
  IgH/c-myc   translocation, the former may have been suffi   cient 
to fully transform the cells. This scenario provides a potential 
role for chromosome 6 losses, and also could explain why all 
CXP   Ig       translocations are not clearly oncogenic, why some 
CXP   Ig       translocations have   IgH   as a partner, and why CXP 
  IgH   translocations can involve either productive or nonpro-
ductive   IgH   alleles. 
  Receptor editing is generally thought to occur in imma-
ture B cells in the BM (  16  ); yet a substantial fraction of CXP 
tumor progenitors appear to have both breaks associated with 
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in quasimonoclonal (QM) mice can express both AID and 
RAG1/2 (  50  ), although other studies of developing B cells in 
WT mice concluded that AID is not expressed in BM B cells 
(  51  ). QM mice harbor a productive IgH knock-in V(D)J allele 
and a homozygous gene-targeted deletion of both J     alleles 
and, thus, only have Ig    -producing B cells (  52  ). The striking 
similarities between immature QM B cells and proposed CXP 
tumor progenitors suggest a potential relationship. In this re-
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